Massive Bio

by Massive Bio  · Based in United States → — AI-Powered Precision Matching for Cancer Clinical Trials and Drug Matching
Hematology Oncology
Website
Claim this tool
Is this the maker? Claim the company →

Free for patients; contact for enterprise pricing

Overview

Massive Bio is a global precision oncology company that leverages artificial intelligence (AI) to connect cancer patients with suitable clinical trials and drug matching options. The platform utilizes advanced AI, including Natural Language Understanding (NLU) and Large Language Models (LLM), to analyze patients’ medical profiles, genomic data, and treatment histories. This enables rapid and accurate identification of relevant oncology and hematology clinical trials worldwide, significantly reducing the time it takes to match patients.

Beyond patient matching, Massive Bio’s solutions also support physicians by streamlining clinical trial referrals and offer services for pharmaceutical companies, Contract Research Organizations (CROs), and hospital networks to accelerate drug development and optimize trial enrollment. The company emphasizes a patient-centric approach, providing concierge services and operating globally in multiple languages.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered precision matching for clinical trials
  • Genomic and medical profile analysis
  • Real-time trial matching and eligibility notification
  • Physician oversight and validation of AI matches
  • Patient concierge and navigation services
  • Mobile application (SYNERGY-AI, Patient Connect)
  • Multi-agent neuro-symbolic AI platform (SYNERGY-AI, DLCTMS)
  • Natural Language Understanding (NLU) for medical records
  • Large Language Model (LLM) and Generative Pre-trained Text (GPT) co-pilots (Dr. Arturo AI, Ask Fiona AI)
  • AI-powered drug matching

Use Cases

  • Connecting cancer patients to suitable clinical trials
  • Streamlining clinical trial referrals for physicians
  • Accelerating drug development and patient enrollment for pharma/CROs
  • Generating real-world evidence (RWE) for research
  • Facilitating virtual tumor boards (VTB)
  • Identifying advanced treatment options for oncologists

What Physicians Need to Know

Patient Portal Integration
Massive Bio's 'Patient Connect' portal allows cancer patients to upload and share medical records, schedule appointments, and access personalized clinical trial matches from a database of nearly 16,000 trials. It integrates with electronic health record (EHR) systems like Oracle Cerner, enabling patients to connect their My Cerner Chart for comprehensive medical record retrieval. The platform supports FHIR standards and Smart Health Cards for enhanced interoperability.
Appointment Scheduling
The Patient Connect portal facilitates appointment scheduling for patients. Massive Bio's concierge services also assist patients with facilitating appointment scheduling with clinical trial sites.
Symptom Checker / Triage
Massive Bio's virtual assistant, DrArturoAI, offers conversational, context-aware AI support, including symptom triage and care navigation.
Multi-Language Patient Support
The Patient Connect portal supports multiple languages to ensure broad accessibility and personalized care globally. Massive Bio provides its services in 11 languages across 18 countries. Consent documents can also be provided in multiple languages.
Health Literacy Adaptation
Massive Bio offers patient education initiatives through partnerships, helping patients understand their options and navigate the clinical trial landscape. Their website provides extensive resources, including blogs, news, videos, webinars, and podcasts on cancer symptoms, treatments, and patient support. The DrArturoAI virtual assistant offers educational guidance, and they provide a psychology-informed storybook, 'Little Tales for Massive Heroes,' for pediatric cancer support.
Chronic Disease Management (Oncology-focused)
While primarily focused on oncology clinical trial matching, Massive Bio's AI technology aims to improve chronic condition support related to clinical trial eligibility. Their follow-up care emphasizes monitoring disease progression and adjusting treatments for chronic conditions within the cancer context.
Medication Adherence Features
Massive Bio has partnered with AdhereTech to provide AI-enabled solutions for measuring, analyzing, and monitoring precision oncology medication adherence for patients in clinical trials and those on commercial treatments. This collaboration aims to offer real-time integrated access to care for cancer patients regarding precision oncology drugs. Massive Bio's AI technology also promotes medication adherence and helps reduce costs.
Patient Education Content
Massive Bio offers a wealth of patient education content via its website, including blogs, news, videos, webinars, and podcasts covering cancer symptoms, treatments, and support. The Patient Connect platform enables patients to download and share personalized clinical trial matching reports with their care team for informed decision-making. The DrArturoAI virtual assistant also provides educational guidance.
Accessibility Compliance
Massive Bio's Synergy-AI platform adheres to international compliance standards such as GDPR, PIPEDA, and HIPAA. They hold CNIL certification for GDPR compliance, allowing secure processing of patient medical records in France. The Patient Connect platform is designed to expand access to treatment regardless of financial or geographical constraints and complies with FHIR standards and Smart Health Cards for data interoperability. They also ensure compliance with Indian data protection laws.
Physician Tip

Leverage Massive Bio's AI-powered platform and 'Trial Relay' solution to significantly reduce the time spent identifying suitable cancer clinical trials for your patients, improving accuracy and outcomes. Utilize the Massive Bio Clinical Network to review pre-screening results and oversee patient enrollment, streamlining the process. Encourage patients to use the Patient Connect portal for self-service record sharing and appointment scheduling, while benefiting from Massive Bio's concierge services for logistical and financial support. Engage with the DrArturoAI co-pilot for physicians for enhanced insights and support. Collaborate with Massive Bio to access a wider range of trial options and facilitate communication with investigators and recruiting sites.

Massive Bio's platform integrates with major electronic health record (EHR) systems like Oracle Cerner to facilitate seamless access and utilization of patient medical records for clinical trial matching. They have an expanded partnership with Datavant for efficient medical record retrieval. The company actively collaborates with pharmaceutical companies, Contract Research Organizations (CROs), patient advocacy groups, and research institutions to enhance clinical trial access and development. Strategic partnerships, such as with Health in Code, enable advanced genomic testing integration for personalized oncology treatment. The platform is built to comply with FHIR standards and Smart Health Cards, promoting broad interoperability within the healthcare ecosystem.

Details

Category Patient Engagement & Education
Pricing Free for patients; contact for enterprise pricing
  • The core clinical trial matching service is free for patients
  • Pricing for enterprise solutions (pharmaceutical companies, CROs, hospital networks) is available upon request
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Unknown AI-estimated

Massive Bio operates in compliance with relevant FDA guidelines for healthcare services and clinical research. The platform provides matching and data analysis services, not direct diagnostic or therapeutic medical devices requiring FDA clearance.
Integrations
EHR Not specified
Specialties Hematology, Oncology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Massive Bio

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Business Wire
Massive Bio Announces Reticulum Nexus - an AI-Driven Multiu2011Agent Platform Orchestrating the End-to-end Patient Journey
Massive Bio unveiled Reticulum Nexus, an AI-powered multi-agent platform designed to improve clinical trial access and operations for cancer patients by unifying clinical and operational intelligence. This platform aims to overcome fragmented data and manual workflows, accelerating patient matching and enrollment.
2025-11
Business Wire
Massive Bio Expands Global Access to Clinical Trials Through AI-Powered Parameterization and Pre-Screening with OpenAI
Massive Bio announced a collaboration with OpenAI to enhance clinical trial accessibility through large-scale parameterization of trial protocols and real-time patient pre-screening capabilities. This initiative is part of OpenAI's Impact Hours program, supporting high-impact projects for large populations.
2026-04
Business Wire
Massive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients
Massive Bio published a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology, demonstrating its AI platform can match cancer patients to clinical trials four times faster than conventional methods. The study involved 3,804 patients with metastatic cancer.
2026-04
Business Wire
Massive Bio Partners With FOMAT to Expand Cancer Patient Prescreening for Clinical Trial Access
Massive Bio partnered with FOMAT, the largest U.S. Embedded Research Organization, to support AI-powered patient prescreening for oncology clinical trials. This collaboration aims to connect more patients to trial opportunities within community-based research networks.
2026-07
Morningstar (via Business Wire)
Massive Bio Announces Partnership with Sequence Me Now to Help Cancer Patients Access Clinical Trials
Massive Bio announced a partnership with Sequence Me Now (SMN), a nonprofit patient advocacy organization, to connect cancer patients with AI-powered clinical trial matching. This collaboration provides a clear path from genomic testing to treatment options.
2026-07
FirstWord HealthTech
Massive Bio debuts AI-based platform to expand cancer trial access
Massive Bio launched its AI-powered multi-agent platform, Reticulum Nexus, at the ESMO AI & Digital Health meeting to enhance clinical trial access and operations for cancer patients. The platform unifies clinical and operational intelligence for patient matching and enrollment.
2025-11
AI Reporter America
Massive Bio Unveiled Reticulum Nexus, Advancing AI Multi-Agent Orchestration Across the Patient Journey
Massive Bio introduced Reticulum Nexus, a patient-centric, multi-agent platform designed to coordinate the entire oncology journey, from initial contact to final enrollment in clinical trials. This system integrates clinical and operational intelligence to improve matching, enrollment, and data collection.
2026-07
Massive Bio
Peer Reviewed Scientific Journal
Massive Bio highlights the importance of peer-reviewed scientific journals in ensuring the quality, validity, and originality of research findings in medicine and clinical oncology. This process involves expert evaluation to uphold scientific standards and provide reliable information.
2026-01

Videos

Product demos, reviews, and walkthroughs for Massive Bio.

View all on YouTube

Frequently Asked Questions

Massive Bio's AI-powered platform, like Trial Relay, allows physicians to securely submit patient information online to receive matches for relevant cancer clinical trials. They provide a detailed trial report and offer concierge services to help patients navigate the process, aiming to streamline referrals and save physician time.
Patients can use the free Patient Connect portal to access personalized clinical trial matches based on their medical profiles, supported in multiple languages. Massive Bio also provides personalized support through concierge services and expert case managers to guide patients through the enrollment process, aiming to ensure a smooth transition and address concerns.
Massive Bio utilizes an AI-powered multi-trial matching system that scans over 19,000 active cancer clinical trials worldwide, aiming to find suitable options faster and more accurately than manual searches. This approach seeks to expand access to trials beyond a physician's immediate knowledge or a single institution, particularly for the 85% of cancer patients treated in community practices.
Massive Bio's clinical trial matching services are provided at no cost to both physicians and patients. Patients may be able to use Flexible Spending Accounts (FSA) or Health Savings Accounts (HSA) for co-pays if their oncologist orders Massive Bio's services and documents the request.
Massive Bio is a data analytics firm and not a healthcare provider, meaning it does not practice medicine or offer medical services. The reports are for informational purposes only and do not substitute for a healthcare professional's judgment, with the primary oncologist retaining sole discretion on their use.
Massive Bio states its platform is HIPAA-compliant and confidential, adhering to strict guidelines and international regulations for privacy. They also integrate with services like Datavant for secure medical record retrieval and align with CMS interoperability frameworks to ensure data protection.
Massive Bio provides a personalized and comprehensive report that includes incremental testing and treatment options, incorporating the treating oncologist's input. This report aims to identify suitable trials based on diagnosis, genomic profile, and location, with the goal of offering best survival and quality of life options.

Related Tools

Stable Health
Stable Health, Inc.
Mental & Behavioral Health AI
Stable Health offers AI-powered solutions for behavioral health practices, including a 24/7 AI front desk, patient messaging, a no-download patient portal for booking and forms, and AI billing for claim scrubbing and denial management. The platform also provides AI reporting from EHR data in plain English and crisis-language escalation.
Paid
AI-Driven Urticaria Support (AIDUS) Chatbot
AI Agent
Patient Engagement & Education
AIDUS is an AI-driven chatbot designed to provide reliable and high-quality information about Chronic Urticaria (CU) to patients and physicians, outperforming general AI models in accuracy for CU-specific questions.
allergoSMART
allergoSMART
Patient Engagement & Education
allergoSMART is the world's first AI-based complete solution for personalized mite allergen avoidance, utilizing intelligent room analysis and integrated encasing solutions.
Virta Health
Virta Health
Endocrinology & Metabolic AI
Virta Health offers a virtual health program focused on reversing Type 2 diabetes, prediabetes, and obesity through a nutrition-first approach, continuous remote care, and personalized coaching.
Hybrid
Novoflow
Novoflow
Patient Engagement & Education
Novoflow deploys AI agents that operate a medical practice’s EHR to automate its biggest operational bottleneck. Live in weeks, without changing how staff work.
Paid
HealthTalk A.I.
HealthTalk A.I.
Patient Engagement & Education
HealthTalk A.I. is a comprehensive patient engagement platform that combines AI-powered scheduling, two-way messaging, digital patient intake, and population health tools to help healthcare organizations engage patients more effectively via their preferred channel.
Subscription-based

See all Patient Engagement & Education tools →

Suggest an Edit → | Last Verified: 2026-04-22 | First Added: 2026-04-22

Investors who backed Massive Bio

Funded through the company that built this tool.

Revo Capital
VC AI T2
Istanbul, Turkey
$1M-$5M
Revo Capital is Istanbul’s largest VC firm, operating around $188M in AUM across multiple funds with Fund II closing at EUR90M and…
AI/ML in Healthcare Diagnostics
AI Tool Finder
AI-powered search. Results may not be comprehensive.